science
Federal Judge Blocks Colorado Price Cap on Amgen Drug Enbrel
A federal judge halted Colorado's first state-level payment limit on the arthritis drug Enbrel. The ruling found Amgen would likely suffer significant harm if the cap took effect.
catholicnewsagency.comAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
A federal judge blocked a Colorado state panel from imposing an upper payment limit on Enbrel, a drug sold by Amgen. The decision pauses implementation of the limit set by the Colorado Prescription Drug Affordability Board. The board was established four years ago to address rising prescription drug costs and can set payment caps for selected medicines.
Background on the Board Several other states have created similar affordability boards with varying rules. Colorado has moved faster than other states in selecting drugs and setting payment limits. The judge determined that Amgen is "likely to be significantly harmed" by the proposed cap.
The ruling applies only to the Enbrel payment limit and does not address the board's broader authority. Amgen did not issue a public statement on the decision.
Transparency
How sources framed this
These outlets didn't split into competing frames — coverage was uniform.
CorroborationModerate · 2 sources
